Drugs Made In America Acquisition (DMAA) Non-Current Deffered Revenue (2025)
Drugs Made In America Acquisition's (DMAA) quarterly Non-Current Deffered Revenue came in at $6.9 million in Q4 2025, little changed on a QoQ basis from $6.9 million in Q3 2025.
Drugs Made In America Acquisition (DMAA) Non-Current Deffered Revenue (2025) Analysis & Trends
Drugs Made In America Acquisition (DMAA) has 1 years of Non-Current Deffered Revenue data on file, last reported at $6.9 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.9 million (changed N/A YoY) and the FY2025 annual result came in at $6.9 million, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $6.9 million in Q4 2025, from $6.9 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $6.9 million in Q1 2025 to a low of $6.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oxley Bridge Acquisition | 585.76 Mn | 585.76 Mn | - | - |
| 2 | Launch Two Acquisition | 557.86 Mn | 557.86 Mn | - | - |
| 3 | Drugs Made In America Acquisition | 507.00 Mn | 507.00 Mn | - | 17.50 Mn |
| 4 | Cantor Equity Partners IV | 468.00 Mn | 468.00 Mn | - | - |
| 5 | GP-Act III Acquisition | 401.06 Mn | 401.06 Mn | - | 13.69 Mn |
| 6 | Aldel Financial | 397.49 Mn | 397.49 Mn | - | - |
| 7 | Republic Digital Acquisition | 389.25 Mn | 388.51 Mn | - | - |
| 8 | Gores Holdings X | 385.06 Mn | 384.87 Mn | - | 10.76 Mn |
| 9 | Agriculture & Natural Solutions Acquisition | 377.29 Mn | 377.04 Mn | - | 12.08 Mn |
| 10 | Drugs Made In America Acquisition | 215.82 Mn | 215.82 Mn | - | 6.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.90 Mn |
| Sep 30, 2025 | 6.90 Mn |
| Jun 30, 2025 | 6.90 Mn |
| Mar 31, 2025 | 6.90 Mn |